Literature DB >> 16815159

A network-based analysis of the late-phase reaction of the skin.

Mikael Benson1, Michael A Langston, Mikael Adner, Bengt Andersson, Asa Torinssson-Naluai, Lars Olaf Cardell.   

Abstract

BACKGROUND: The late-phase reaction (LPR) of the skin is an in vivo model of allergic inflammation.
OBJECTIVE: We sought to identify disease-associated pathways in the LPR using a network-based analysis.
METHODS: The LPR was examined by means of DNA microarray analysis of skin biopsy specimens from 10 patients with allergic rhinitis and 10 healthy control subjects. The results were further analyzed in 2 different materials consisting of nasal fluids and allergen-challenged CD4(+) T cells from patients with allergic rhinitis.
RESULTS: The DNA microarray analysis revealed several genes of known relevance to allergy. The eosinophil marker Charcot-Leyden crystal protein (CLC) that encodes Charcot-Leyden crystal protein differed most in expression. A network-based analysis showed upregulation of IL-4- and CCL4-dependent pathways and downregulation of a TGF-beta-induced pathway. CCL4 is expressed by CD4(+) T cells and chemotactic for eosinophils. We hypothesized that allergen induces release of CCL4 from T(H)2 cells and that this contributes to influx of eosinophils. Further analysis showed increase of CCL4 protein in nasal fluids from allergic patients during the season. Allergen challenge of PBMCs resulted in proliferation of T(H)2 cells and increased production of CCL4 in CD4(+) T cells from allergic patients. An analysis of the DNA microarray data revealed a significant correlation between CCL4 and the eosinophil marker CLC.
CONCLUSION: A network-based analysis of the LPR showed increased activity of IL-4- and CCL4- dependent pathways and downregulation of the TGF-beta-induced pathway. Allergen-induced release of CCL4 from T(H)2 cells might contribute to influx of eosinophils during the LPR. CLINICAL IMPLICATIONS: Involvement of multiple interacting pathways indicates that it might be difficult to identify one single mediator as a biomarker or drug target in allergic inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815159     DOI: 10.1016/j.jaci.2006.03.006

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

1.  A generally applicable translational strategy identifies S100A4 as a candidate gene in allergy.

Authors:  Sören Bruhn; Yu Fang; Fredrik Barrenäs; Mika Gustafsson; Huan Zhang; Aelita Konstantinell; Andrea Krönke; Birte Sönnichsen; Anne Bresnick; Natalya Dulyaninova; Hui Wang; Yelin Zhao; Jörg Klingelhöfer; Noona Ambartsumian; Mette K Beck; Colm Nestor; Elsa Bona; Zou Xiang; Mikael Benson
Journal:  Sci Transl Med       Date:  2014-01-08       Impact factor: 17.956

2.  Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.

Authors:  Joel Pekow; Urszula Dougherty; Yong Huang; Edward Gometz; Jeff Nathanson; Greg Cohen; Shawn Levy; Masha Kocherginsky; Nanda Venu; Maria Westerhoff; John Hart; Amy E Noffsinger; Stephen B Hanauer; Roger D Hurst; Alessandro Fichera; Loren J Joseph; Qiang Liu; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

3.  Highly interconnected genes in disease-specific networks are enriched for disease-associated polymorphisms.

Authors:  Fredrik Barrenäs; Sreenivas Chavali; Alexessander Couto Alves; Lachlan Coin; Marjo-Riitta Jarvelin; Rebecka Jörnsten; Michael A Langston; Adaikalavan Ramasamy; Gary Rogers; Hui Wang; Mikael Benson
Journal:  Genome Biol       Date:  2012-06-15       Impact factor: 13.583

4.  A module-based analytical strategy to identify novel disease-associated genes shows an inhibitory role for interleukin 7 Receptor in allergic inflammation.

Authors:  Reza Mobini; Bengt A Andersson; Jonas Erjefält; Mirjana Hahn-Zoric; Michael A Langston; Andy D Perkins; Lars Olaf Cardell; Mikael Benson
Journal:  BMC Syst Biol       Date:  2009-02-12

5.  Dysregulation of complement system and CD4+ T cell activation pathways implicated in allergic response.

Authors:  Alexessander Couto Alves; Sören Bruhn; Adaikalavan Ramasamy; Hui Wang; John W Holloway; Anna-Liisa Hartikainen; Marjo-Riitta Jarvelin; Mikael Benson; David J Balding; Lachlan J M Coin
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

6.  Potential Involvement of Type I Interferon Signaling in Immunotherapy in Seasonal Allergic Rhinitis.

Authors:  Lina Mattson; Antonio Lentini; Danuta R Gawel; Tejaswi V S Badam; Mikael Benson; Torbjorn Ledin; Colm E Nestor; Mika Gustafsson; Jordi Serra-Musach; Janne Bjorkander; Zou Xiang; Huan Zhang
Journal:  J Immunol Res       Date:  2016-12-19       Impact factor: 4.818

7.  MicroRNAs act complementarily to regulate disease-related mRNA modules in human diseases.

Authors:  Sreenivas Chavali; Sören Bruhn; Katrin Tiemann; Pål Saetrom; Fredrik Barrenäs; Takaya Saito; Kartiek Kanduri; Hui Wang; Mikael Benson
Journal:  RNA       Date:  2013-09-23       Impact factor: 4.942

8.  Integrated genomic and prospective clinical studies show the importance of modular pleiotropy for disease susceptibility, diagnosis and treatment.

Authors:  Mika Gustafsson; Måns Edström; Danuta Gawel; Colm E Nestor; Hui Wang; Huan Zhang; Fredrik Barrenäs; James Tojo; Ingrid Kockum; Tomas Olsson; Jordi Serra-Musach; Núria Bonifaci; Miguel Angel Pujana; Jan Ernerudh; Mikael Benson
Journal:  Genome Med       Date:  2014-02-26       Impact factor: 11.117

9.  Immediate type hypersensitivity and late phase reaction occurred consecutively in a patient receiving ethambutol and levofloxacin.

Authors:  Yukihiko Kato; Yu Sato; Miho Nakasu; Ryoji Tsuboi
Journal:  Allergy Asthma Clin Immunol       Date:  2018-04-03       Impact factor: 3.406

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.